PDF herunterladen
Pneumologie 2002; 56(11): 704-738
DOI: 10.1055/s-2002-35553
Leitlinie
© Georg Thieme Verlag Stuttgart · New York

Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD)

Guidelines for the Diagnosis and Treatmental Chronic Obstructive Bronchitits and Pulmonary Emphysema Issued by Deutsche Atemwegsliga and Deutsche Gesellschaft für PneumologieH.  Worth, R.  Buhl, U.  Cegla, C.  P.  Criée, A.  Gillissen, P.  Kardos, D.  Köhler, H.  Magnussen, R.  Meister, D.  Nowak, W.  Petro, K.  F.  Rabe, G.  Schultze-Werninghaus, H.  Sitter, H.  Teschler, T.  Welte, R.  Wettengel
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
20. November 2002 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Inhalt Seite Vorwort 705 Ziele und Anwendungsbereich der Leitlinie 705 Entwicklungsprozess der Leitlinie 705 Sponsoring 706 Strategien zur Förderung der Verbreitung und Implementierung der Leitlinie 706 Weiterentwicklung der COPD-Leitlinie 707 Definitionen 707 Epidemiologie und sozialökonomische Bedeutung 707 Verlauf der Erkrankung 708 Management der COPD 708 Diagnostik 708 Untersuchungsmethoden 708 Diagnostisches Vorgehen bei Verdacht auf COPD 711 Schweregradeinteilung 712 Differenzialdiagnose 713 Verlaufsuntersuchungen 713 Therapie 714 Prävention 714 - Raucherentwöhnung 714 - Schutzimpfungen 715 Langzeitbehandlung der stabilen COPD 715 - Bronchodilatatoren 716 - Glukokortikoide 718 - Mukopharmaka 719 - Immunmodulatoren 719 - Antitussiva 719 - Atemstimulanzien 719 - Analgetika 719 - Substitutionstherapie bei Alpha-1-Proteinase-Inhibitor-Mangel 719 - Behandlung der Osteoporose 720 Nichtmedikamentöse Therapie 720 - Ernährung 720 - Patientenschulung 720 - Physiotherapie 721 - Pneumologische Rehabilitation 721 - Langzeitbehandlung mit O2 723 - Heimbeatmung 723 - Operative Therapieverfahren 724 Management der akuten Exazerbation 725 - Diagnostik 726 - Therapie der Exazerbation 726 - Betreuung des Patienten nach akuter Exazerbation 730 - Exazerbationsprophylaxe 730 Gemeinsamkeiten und Unterschiede der Leitlinie im Vergleich zur GOLD-Leitlinie 730 Appendix A: Berufsbedingte Bronchitis - Arbeitsmedizinische Aspekte der chronischen Bronchitis 731 Appendix B: Teilnehmerliste der Konsensus-Konferenz 732 Literaturverzeichnis 733

Literatur

  • 1 Wettengel R, Böhning W, Cegla U. et al . Empfehlungen der Deutschen Atemwegsliga zur Behandlung von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem.  Med Klin. 1995;  90 3-7
    PubMedGoogle Scholar
  • 2 Pauwels R A, Buist A S, Calverley P MA. et al . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2001;  163 1256-1276
    CrossrefPubMedGoogle Scholar
  • 3 ATS Statement . Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 1995;  152 S77-S120
    PubMedGoogle Scholar
  • 4 Siafakas N M, Vermeire P, Pride N B. et al . ERS-Consensus statement. Optimal assessment and management of chronic obstructive pulmonary disease.  Eur Respir J. 1995;  8 1388-1420
    PubMedGoogle Scholar
  • 5 BTS . Guidelines for the management of chronic obstructive pulmonary disease.  Thorax. 1997;  52 (Suppl 5) S1-S28
    CrossrefPubMedGoogle Scholar
  • 6 Canadian Respiratory Review Panel .Guidelines for the treatment of chronic obstructive pulmonary disease (COPD). Monograph 1998
    Google Scholar
  • 7 Laitinen L, Koskela K. et al . Chronic bronchitis and chronic obstructive pulmonary disease: Finnish national guidelines for prevention and treatment 1998 - 2007.  Respir Med. 1999;  93 207-332
    PubMedGoogle Scholar
  • 8 Lorenz W, Ollenschläger G. et al . Das Leitlinienmanual von AWMF und ÄZQ.  ZaeFQ. 2001;  95 (Suppl. I) 41-43
    PubMedGoogle Scholar
  • 9 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften .Erarbeitung von Leitlinien für Diagnostik und Therapie. Methodische Empfehlungen. Abrufbar unter: http://www.uni-duesseldorf.de/WWW/AWMF
    Google Scholar
  • 10 Society for Medical Decision Making . Committee on standardization of clinical algorithms. Proposals for clinical algorithm standards.  Med Decis Making. 1992;  12 149-154
    PubMedGoogle Scholar
  • 11 Report of an expert committee . Definition and diagnosis of pulmonary disease with special reference to chronic bronchitis and emphysema.  WHO Techn Rep Ser. 1961;  213 14-19
    PubMedGoogle Scholar
  • 12 Ciba guest symposium report . Terminology, definitions and classifications of chronic pulmonary emphysema and related conditions.  Thorax. 1959;  14 286-299
    CrossrefPubMedGoogle Scholar
  • 13 Konietzko N, Fabel H. Weißbuch Lunge 2000. Stuttgart-New York: Thieme
    Google Scholar
  • 14 Statistisches Bundesamt .Statistisches Jahrbuch, Jahrgänge 1968 - 1999. Stuttgart-Mainz: Kohlhammer
    Google Scholar
  • 15 Murray C JL, Lopez A D. The global burden of disease: A comprehensive assessment of mortality and disability from diseases. Injuries and risk factors in 1990 and projected to 2020. Cambridge: Harvard University Press 1996
    Google Scholar
  • 16 Lopez A D, Murray C JL. The global burden of disease, 1990 - 2020.  Nature Med. 1998;  4 1241-1243
    CrossrefPubMedGoogle Scholar
  • 17 Rychlik R, Pfeil T, Daniel D. et al . Zur sozioökonomischen Relevanz akuter Exacerbationen der chronischen Bronchitis in der Bundesrepublik Deutschland.  Dtsch Med Wschr. 2001;  126 353-359
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 18 Laurell C B, Eriksson S. The electrophoretic alpha-1 globulin pattern of serum in alpha-1 antitrypsin deficiency.  Scand J Clin Lab Invest. 1963;  15 132-140
    CrossrefPubMedGoogle Scholar
  • 19 Orie N GM, Sluiter H J, De Vreis K. et al .The host factor in bronchitis. In: Orie NGM, Sluiter HJ, (eds). Bronchitis, an international symposium. Assen, Netherlands: Royal Vangorum 1961: 43-59
    Google Scholar
  • 20 Svanes C, Omenaas E, Heuch J M. et al . Birth characteristics and asthma symptoms in young adults: results from a population-based cohort study in Norway.  Eur Respir J. 1998;  12 1366-1370
    CrossrefPubMedGoogle Scholar
  • 21 Todisco T, de Benedictis F M, Iannacci L. et al . Mild prematurity and respiratory functions.  Eur J Pediatr. 1993;  152 55-58
    CrossrefPubMedGoogle Scholar
  • 22 Stein C E, Kumaran K, Fall C H. et al . Relation of fetal growth to adult lung function in South India.  Thorax. 1997;  52 895-899
    CrossrefPubMedGoogle Scholar
  • 23 Morgan W J. Maternal smoking and infant lung function: further evidence for an in utero effect.  Am J Respir Crit Care Med. 1998;  158 689-690
    CrossrefPubMedGoogle Scholar
  • 24 U. S. Surgeon General .The health consequences of smoking: chronic obstructive pulmonary disease. Washington DC.: U. S. Department of health and human services 1984 Publication No. 84 - 50 205
    Google Scholar
  • 25 Leuenberger P, Schwartz J, Ackermann-Liebrich U. et al . Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA Study). Swiss Study on air pollution and lung diseases in adults. SAPALDIA Team.  Am J Respir Crit Care Med. 1994;  150 1222-1228
    PubMedGoogle Scholar
  • 26 Dayal H H, Khuder S, Sharrar R. et al . Passive smoking in obstructive respiratory disease in an industrialized urban population.  Environ Res. 1994;  65 161-171
    CrossrefPubMedGoogle Scholar
  • 27 Holt P G. Immune and inflammatory function in cigarette smokers.  Thorax. 1987;  42 241-249
    PubMedGoogle Scholar
  • 28 Kauffmann F, Droulet D, Lellouch J. et al . Twelve years spirometric changes among Paris area workers.  Int J Epidemiol. 1979;  8 201-212
    CrossrefPubMedGoogle Scholar
  • 29 Niewoehner D E. Anatomic and pathophysiological correlations in COPD In Baum Gl, Crapo JD, Celli BR, Karlinsky JB, (eds.) Textbook of pulmonary diseases. Philadelphia: Lippincott-Raven 1998: 823-842
  • 30 Chen J C, Mannino M D. Worldwide epidemiology of chronic obstructive pulmonary disease.  Current Opin Pulmon Med. 1995;  5 93-99
    PubMedGoogle Scholar
  • 31 Behera D, Jindal S K. Respiratory symptoms in Indian women using domestic cooking fuels.  Chest. 1991;  100 385-388
    CrossrefPubMedGoogle Scholar
  • 32 Georgopoulos D, Anthonisen N R. Symptoms and signs of COPD. In: Cherniack NS (ed). Chronic obstructive pulmonary disease. Toronto: Saunders 1991: 357-363
    Google Scholar
  • 33 Taube M D, Lehnigk B, Paasch K. et al . Factor analysis of changes in dyspnea and lung function parameters after bronchodilatation in chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2000;  162 216-220
    CrossrefPubMedGoogle Scholar
  • 34 O'Donnell D E, Lam M, Webb K A. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 1998;  158 1557-1565
    PubMedGoogle Scholar
  • 35 O'Donnell D E, Lam M, Webb K A. Spirometric correlates for improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 1999;  160 542-549
    PubMedGoogle Scholar
  • 36 Marin J M, Carrizo S J, Gascon M. et al . Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2001;  163 1395-1399
    PubMedGoogle Scholar
  • 37 Seemungal T A, Donaldson G C, Bhownik A. et al . Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2000;  161 1608-1613
    CrossrefPubMedGoogle Scholar
  • 38 Traver G A, Cline M G, Burrows B. Predictors of mortality in COPD.  Am Rev Respir Dis. 1979;  119 895-902
    PubMedGoogle Scholar
  • 39 Burrows B. The course and prognosis of different types of chronic airflow limitation in a general population sample from Arizona: comparison with the Chicago “COPD” series.  Am Rev Respir Dis. 1989;  140 92-94
    PubMedGoogle Scholar
  • 40 Quanjer P H. Standardised lung function testing. Official statement of the European Respiratory Society.  Eur Respir J. 1993;  6 (Suppl 16) 5-40
    PubMedGoogle Scholar
  • 41 Tweeddale P W, Alexander F, McHardy G JR. Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects.  Thorax. 1987;  42 87-90
    PubMedGoogle Scholar
  • 42 Guyatt G H, Townsend M, Nogradi S. et al . Acute response to bronchodilator. An imperfect guide for bronchodilator therapy in chronic airflow limitation.  Arch Intern Med. 1988;  148 1949-1952
    CrossrefPubMedGoogle Scholar
  • 43 Berger R, Smith D. Effect of an inhaled metaproterenol on exercise performance in patients with stable “fixed” airway obstruction.  Am Rev Respir Dis. 1988;  138 626-629
    PubMedGoogle Scholar
  • 44 Gross N, Tashkin D, Miller R. et al . Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group.  Respiration. 1998;  65 354-362
    CrossrefPubMedGoogle Scholar
  • 45 Guyatt G H, Townsend M, Pugsley S O. et al . Bronchodilators in chronic air-flow limitation: effects on airway function, exercise capacity and quality of life.  Am Rev Respir Dis. 1987;  135 1069-1074
    PubMedGoogle Scholar
  • 46 Callahan C M, Cirrus R S, Katz B P. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis.  Ann Intern Med. 1991;  114 216-223
    PubMedGoogle Scholar
  • 47 American Thoracic Society . Lung function testing: selection of reference values and interpretation strategies.  Am Rev Respir Dis. 1991;  144 202-218
    PubMedGoogle Scholar
  • 48 Roberts C M, Bugler J R, Melchor R. et al . Value of pulse oximetry for long-term oxygen therapy requirement.  Eur Respir J. 1993;  6 559-562
    CrossrefPubMedGoogle Scholar
  • 49 Hughes J MB, Pride N B. In defense of the carbon monoxide transfer coefficent Kco(TL/VA).  Eur Respir J. 2001;  17 168-174
    CrossrefPubMedGoogle Scholar
  • 50 McLean A, Warren P M, Gilooly M. et al . Microscopic and macroscopic measurement of emphysema: relation to carbon monoxide transfer.  Thorax. 1992;  47 14-19
    PubMedGoogle Scholar
  • 51 Gevenois P A, de Vuyst P, de Maertelaer V. et al . Comparison of computed density and microscopic morphometry in pulmonary emphysema.  Am J Respir Crit Care Med. 1996;  154 187-192
    PubMedGoogle Scholar
  • 52 Gould G A, Redpath A T, Ryan M. et al . Lung CT density correlates with measurements of airflow limitation and the diffusing capacity.  Eur Respir J. 1991;  4 141-146
    PubMedGoogle Scholar
  • 53 Worth H, Breuer H-W M, Dorow P. et al .Deutsche Gesellschaft für Pneumologie. Empfehlungen zur Durchführung und Bewertung von Belastungsuntersuchungen in der Pneumologie. 52 1998: 225-231
    Google Scholar
  • 54 Thurlbeck W M, Simon G. Radiographic appearance of the chest in emphysemas.  Am J Roentgenol. 1978;  130 429-440
    PubMedGoogle Scholar
  • 55 Morgan M DL, Denison D M, Stricklund B. Value of computed tomography for selecting patients with bullous emphysema.  Thorax. 1986;  41 855-862
    PubMedGoogle Scholar
  • 56 Lehtonen J, Sutinen S, Ikaheimo M. et al . Electrocardiographic criteria for the diagnosis of right ventricular hypertrophy verified at autopsy.  Chest. 1988;  93 839-842
    PubMedGoogle Scholar
  • 57 Niedermeier J, Barner A, Borst M. et al . Deutsche Gesellschaft für Pneumologie. Empfehlungen zur Anwendung der Echokardiographie in der pneumologischen Diagnostik.  Pneumologie. 1998;  52 519-521
    PubMedGoogle Scholar
  • 58 Worth H, Adam D, Handrick W. et al . Prophylaxe und Therapie von bronchopulmonalen Infektionen. Empfehlungen der Deutschen Atemwegsliga.  Pneumologie. 1998;  52 232-237
    PubMedGoogle Scholar
  • 59 O'Donnell D E, Forkert L, Webb K A. Evaluation of bronchodilator responses in patients with “irreversible” emphysema.  Eur Respir J. 2001;  18 914-920
    CrossrefPubMedGoogle Scholar
  • 60 Begin P, Grassino A. Inspiratory muscle dysfunction and chronic hypercapnia in chronic obstructive pulmonary disease.  Am Rev Respir Dis. 1991;  143 901-903
    PubMedGoogle Scholar
  • 61 Baldi S, Miniati M, Bellina C R. et al . Relationship between extent of pulmonary emphysema by high-resolution computed tomography and lung elastic recoil in patients with chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2001;  169 585-589
    PubMedGoogle Scholar
  • 62 Wolkove N, Dacezman E, Colacone A. et al . The relationship between pulmonary function and dyspnoea in obstructive lung disease.  Chest. 1989;  96 1247-1251
    PubMedGoogle Scholar
  • 63 Connolly M C, Crowley J J, Charan N B. et al . Reduced subjective awareness of bronchoconstriction by metacholine in elderly asthmatic and normal subjects as measured on a simple awareness scale.  Thorax. 1992;  47 410-413
    CrossrefPubMedGoogle Scholar
  • 64 Wilson D H, Wakefield M A, Steven I D. et al . “Sick of smoking” evaluation of a targeted minimal smoking cessation intervention in general practice.  Med J Aust. 1990;  152 518-521
    PubMedGoogle Scholar
  • 65 Britton J, Knox A. Helping people to stop smoking: the new smoking cessation guidelines.  Thorax. 1999;  54 1-2
    PubMedGoogle Scholar
  • 66 Kottke T E, Ballista R N, de Friese G H. et al . Attributes of successful smoking cessation interventions in medical practise. A meta-analysis of 39 controlled trials.  JAMA. 1988;  259 2883-2889
    CrossrefPubMedGoogle Scholar
  • 67 Ockene J K, Kristeller J, Goldberg R. et al . Increasing the efficacy of physician delivered smoking interventions: a randomized controlled clinical trial.  J Gen Intern Med. 1991;  6 1-9
    PubMedGoogle Scholar
  • 68 Fiore M C, Bailey W C, Cohen S J. Smoking cessation: information for specialists. U.S. department of health and human services. Public health service. Agency for health care policy and research and centers for disease control and prevention. Rockville: M.D. AHCPR 1996 Publication No. 96 - 0694
    Google Scholar
  • 69 The tobacco use and dependence clinical practice guideline panel, staff and consortium repesentatives . A clinical practice guideline for treating tobacco use and dependence.  JAMA. 2000;  83 3244-3254
    PubMedGoogle Scholar
  • 70 American Medical Association .Guidelines for the diagnosis and treatment of nicotine dependence. How to help patients stop smoking. Washington D.C.: American Medical Association 1994
    Google Scholar
  • 71 Glynn T J, Manley M W. How to help your patients stop smoking. A national cancer institute manual for physicians. Bethesda M.D. U.S. Department of health and human service, public health service. National institutes of health. National Cancer Institute NIH Publication 90 - 3064 1990
    Google Scholar
  • 72 Anthonisen N R, Connett J E, Kiley J P. et al . Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: The Lung Health Study.  JAMA. 1994;  272 1497-1505
    CrossrefPubMedGoogle Scholar
  • 73 Arzneimittelkommission der Deutschen Ärzteschaft .Empfehlungen zur Therapie der Tabakabhängigkeit. Köln: AVP-Reihe 2001
    Google Scholar
  • 74 Jorenby R E, Leischow S J, Nides M A. et al . A controlled trial of sustained release bupropion, a nicotine patch, or both for smoking cessation.  N Engl J Med. 1999;  340 685-691
    CrossrefPubMedGoogle Scholar
  • 75 Tashkin D P, Kanner R J, Buist S. et al . Smoking cessation in patients with chronic obstructive pulmonary disease: a double blind, placebo-controlled randomised trial.  Lancet. 2001;  357 1571-1575
    CrossrefPubMedGoogle Scholar
  • 76 WHO .Tobacco free initiative: Policies for public Health. www.who//int/toh/world nottobacco 99
    Google Scholar
  • 77 Fiore M C, Bailey W C, Cohen S J. et al .Treating tobacco use as dispendence: A clinical practical guideline. A public health service report. Rockville, M.D.: US Dept Health and Human Services 2000
    Google Scholar
  • 78 Schwartz J L. Review and evalution of smoking cessation methods: United States and Canada, 1978 - 1985. Bethesda, M.D.: National Institute of Health 1987 NIH publication 87 - 2940
    Google Scholar
  • 79 Fiore M C, Smith S S, Jorenby D E. et al . The effectiveness of the nicotine patch for smoking cessation. A meta-analysis.  JAMA. 1994;  271 1940-1947
    CrossrefPubMedGoogle Scholar
  • 80 Sachs D E, Benowitz N L. Individual medical treatment for tobacco dependence [editorial; comment].  Eur Respir J. 1996;  9 629-631
    CrossrefPubMedGoogle Scholar
  • 81 Nichol K, Margolis L, Wourenma J. et al . The efficacy and cost effectiveness of vaccination against influenza among elderley persons living in the community.  N Engl J Med. 1994;  331 778-784
    CrossrefPubMedGoogle Scholar
  • 82 Hak E, van Essen G A, Buskens E. et al . Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general based clinical prospective cohort study in Utrecht. The Netherlands.  J Epidemiol Community Health. 1998;  52 120-125
    PubMedGoogle Scholar
  • 83 Simberkoff M S, Cross A P, Al-Ibrahim M. et al . Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study.  N Engl J Med. 1986;  315 1318-1327
    CrossrefPubMedGoogle Scholar
  • 84 Williams J HJ, Moser K M. Pneumococcal vaccine and patients with chronic lung disease.  Ann Intern Med. 1986;  104 106-109
    PubMedGoogle Scholar
  • 85 Christenson B, Lundbergh P, Hedlund J. et al . Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study.  Lancet. 2001;  357 1008-1011
    CrossrefPubMedGoogle Scholar
  • 86 Davis A L, Aranda P, Schiffman G. et al . Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study.  Chest. 1994;  92 204-212
    PubMedGoogle Scholar
  • 87 Schaberg T. Pneumokokkenschutzimpfung.  Pneumologie. 2001;  55 543-545
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 88 Ständige Impfkommission am Robert Koch-Institut (STIKO) .Epidemiologisches Bulletin des RKI. 28 2001: 203-218
    Google Scholar
  • 89 Pauwels R A, Lofdahl C G, Laitinen L A. et al . Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking.  N Engl J Med. 1999;  340 1948-1953
    CrossrefPubMedGoogle Scholar
  • 90 Vestbo J, Sorensen T, Langer P. et al . Longterm effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial.  Lancet. 1999;  355 1819-1823
    PubMedGoogle Scholar
  • 91 Burge P S, Calverley M A, Jones P W. et al . Randomised, placebo-controlled study of fluticasone proprionate in patients with moderate to severe chronic obstructive pulmonary disease; the Isolde trial.  Br Med J. 2000;  320 1297-1303
    CrossrefPubMedGoogle Scholar
  • 92 The Lung Health Study Research Group . Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease.  N Engl J Med. 2000;  343 1902-1909
    CrossrefPubMedGoogle Scholar
  • 93 Van Schayck C P, Dompeling E, van Heerwaarden C LA. et al . Bronchodilator treatment in modern asthma or chronic bronchitis. Continuous or on demand. A randomised controlled study.  BMJ. 1991;  303 1426-1431
    PubMedGoogle Scholar
  • 94 Voshaar T, App E M, Berdel D. et al . Empfehlungen für die Auswahl von Inhalationssystemen für die Medikamentenverabreichung.  Pneumologie. 2001;  55 579-586
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 95 Nisar M, Earis J E, Pearson M G. et al . Acute bronchodilator trials in chronic obstructive pulmonary disease.  Am Rev Respir Dis. 1992;  146 555-559
    PubMedGoogle Scholar
  • 96 Ulrik C S. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study.  Thorax. 1995;  50 750-754
    PubMedGoogle Scholar
  • 97 Grove A, Lipworth B J, Reid P. et al . Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease.  Thorax. 1996;  51 689-693
    CrossrefPubMedGoogle Scholar
  • 98 Boyd G, Mirice A H, Pounsford J G. et al . An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD).  Eur Respir J. 1997;  10 815-821
    PubMedGoogle Scholar
  • 99 Maesen B LP, Wedermann C JJ, Duarkens V AM. et al . Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease.  Eur Respir J. 1999;  13 1103-1108
    CrossrefPubMedGoogle Scholar
  • 100 Jones P W, Bosh T K. Quality of life changes in COPD patients treated with salmeterol.  Am J Respir Crit Care Med. 1997;  155 1283-1289
    PubMedGoogle Scholar
  • 101 Cazzola M, Imperatore F, Salzillo A. et al . Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmia.  Chest. 1998;  114 411-415
    CrossrefPubMedGoogle Scholar
  • 102 Karpel J P, Pesin J, Greenberg D. et al . A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exazerbations of COPD.  Chest. 1990;  98 835-839
    PubMedGoogle Scholar
  • 103 Patrick D M, Dales R E, Stark R M. et al . Severe exacerbations of COPD and asthma. Incremental benefit of adding ipratropium to usual therapy.  Chest. 1990;  98 295-297
    PubMedGoogle Scholar
  • 104 Braun S R, Mc Kenzie W N, Copeland C. et al . A comparison of the effect of ipratropium and albuterol in the treatment of chronic airways disease.  Arch Intern Med. 1989;  149 544-547
    CrossrefPubMedGoogle Scholar
  • 105 Tashkin D P, Ashutosh K, Bleeker E R. et al . Comparison of the anticholinergic bronchodilator ipratropiumbromide with metaproterenol in chronic obstructive pulmonary disease: a multicenter study.  Am J Med. 1986;  81 (Suppl. 5a) 1411-1419
    PubMedGoogle Scholar
  • 106 COMBIVENT Inhalation Aerosol Study Group . In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial.  Chest. 1994;  105 1411-1419
    PubMedGoogle Scholar
  • 107 Rennard S I. Extended bronchodilator treatment in chronich obstructive pulmonary disease.  Eur Respir Rev. 1996;  6 282-286
    PubMedGoogle Scholar
  • 108 Barnes P J. The pharmacological properties of tiotropium.  Chest. 2000;  117 63-66
    CrossrefPubMedGoogle Scholar
  • 109 Calverley P MA. The future of tiotropium.  Chest. 2000;  117 67-69
    CrossrefPubMedGoogle Scholar
  • 110 Casaburi R, Mahler D A, Jones P W. et al . A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.  Eur Respir J. 2002;  19 217-224
    CrossrefPubMedGoogle Scholar
  • 111 Vincken W, von Noord J A, Greefhorst A P. et al . Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.  Eur Respir J. 2002;  19 209-216
    CrossrefPubMedGoogle Scholar
  • 112 Murciano D, Auclair M-A, Pariente R. et al . A randomized controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease.  N Eng J Med. 1989;  320 1512-1525
    PubMedGoogle Scholar
  • 113 Mc Kay S E, Howie C A, Thomson A H. et al . Value of theophylline treatment in patients handicapped by chronic obstructive pulmonary disease.  Thorax. 1993;  48 227-232
    PubMedGoogle Scholar
  • 114 Mulloy E, Mc Nicholas W T. Theophylline improves gas exchange during rest, exercise and sleep in severe chronic obstructive pulmonary disease.  Am Rev Respir Dis. 1993;  148 1030-1036
    PubMedGoogle Scholar
  • 115 Evans W W. Plasma theophylline concentrations, six minute walking distances and breathlessness in patients with chronic airflow obstruction.  BMJ. 1984;  289 1649-1651
    PubMedGoogle Scholar
  • 116 Cooper C B, Davidson A C, Cameron I R. Aminophylline, respiratory muscle strength and exercise tolerance in chronic obstructive airway disease.  Clin Respir Physiol. 1987;  23 15-22
    PubMedGoogle Scholar
  • 117 Murciano D, Aubier M, Lecolguic Y. et al . The effects of theophylline on diaphragmatic strength an exercise tolerance in patients with chronic obstructive pulmonary disease.  N Engl J Med. 1984;  322 349-353
    PubMedGoogle Scholar
  • 118 Williamson B H, Milligan C, Griffiths K. et al . An assessment of major and minor side effects of theophylline.  Aust NZ J Med. 1988;  19 539
    PubMedGoogle Scholar
  • 119 Kirsten D, Wegner R E, Jörres R A. et al . Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease.  Chest. 1993;  104 1101-1107
    PubMedGoogle Scholar
  • 120 The COMBIVENT Inhalation Solution Study Group . Routine nebulized ipratropium and albuterol together are better than either alone in COPD.  Chest. 1997;  112 1514-1521
    PubMedGoogle Scholar
  • 121 Taylor D R, Buick B, Kinney C. et al . The efficacy of orally administered theophylline, inhaled salbutamol and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible airflow obstruction.  Am J Respir Dis. 1985;  131 747-751
    PubMedGoogle Scholar
  • 122 Van Noord J A, de Munck D R, Bantje T A. et al . Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium.  Eur Respir J. 2000;  15 878-885
    CrossrefPubMedGoogle Scholar
  • 123 D'Urzo A D, de Salvo M C, Ramirez-Rivera A. et al . In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium.  Chest. 2001;  119 1347-1356
    CrossrefPubMedGoogle Scholar
  • 124 O'Driscoll B R, Kay E A, Taylor R J. et al . A long-term prospective assessment of home nebulizer treatment.  Respir Med. 1992;  S6 317-325
    PubMedGoogle Scholar
  • 125 Washkin D P, Bleecker E, Braun S. et al . Results of a multicenter study of nebulized inhalant bronchodilator solutions.  Am J Med. 1996;  100 62-69
    CrossrefPubMedGoogle Scholar
  • 126 Senderovitz T, Vestbo J, Frandsen J. et al . Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society or Respiratory Medicine.  Respir Med. 1999;  93 715-718
    PubMedGoogle Scholar
  • 127 Rice K L, Rubins J B, Lebhahn F. et al . Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial.  Am J Respir Crit Care Med. 2000;  162 174-178
    PubMedGoogle Scholar
  • 128 Decramer M, Lacquet L M, Fagard R. et al . Corticosteroids contribute to muscle weakness in chronic airflow obstruction.  Am J Respir Crit Care Med. 1994;  150 11-16
    CrossrefPubMedGoogle Scholar
  • 129 Decramer M, Stas K J. Corticosteroid-induced myopathy involving respiratory muscles in patients with chronic obstructive pulmonary disease or asthma.  Am J Respir Dis. 1992;  146 800-802
    PubMedGoogle Scholar
  • 130 Schols A MWJ, Wesseling G, Keser A DM. et al . Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids.  Eur Respir J. 2001;  17 337-342
    CrossrefPubMedGoogle Scholar
  • 131 Grassi C. and the multicenter Study Group . Longterm oral acetylcysteine in chronic bronchitis. A double blind controlled study.  Eur J Respir Dis. 1980;  61 (Suppl. 111) 93-108
    PubMedGoogle Scholar
  • 132 Boman G, Bäcker U, Larsson S. et al . Oral acetylcysteine reduces exacerbation rate in chronic bronchitis. Report of a trial organized by the Swedish Society for Pulmonary Diseases.  Eur J Respir Dis. 1983;  64 405-415
    PubMedGoogle Scholar
  • 133 Jackson M, Barnes J, Cooksey P. Efficacy and tolerability of oral acetylcysteine (Fabrol) in chronic bronchitis: A double-blind placebo-controlled study.  J Int Med Res. 1984;  12 198-205
    PubMedGoogle Scholar
  • 134 Mc Gavin C R. and the British Thoracic Society Research Committee . Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airway obstruction.  Thorax. 1985;  40 832-835
    PubMedGoogle Scholar
  • 135 Meister R. Langzeittherapie mit Acetylcystein Retard-Tabletten bei Patienten mit chronischer Bronchitis. Eine doppelblinde-placebokontrollierte Studie.  Forum Prakt Allg Arzt. 1986;  25 18-22
    PubMedGoogle Scholar
  • 136 Parr G D, Huitson A. Oral fabrol (oral N-acetylcysteine) in chronic bronchitis.  Br J Dis Chest. 1987;  81 341-348
    CrossrefPubMedGoogle Scholar
  • 137 Rasmussen J B, Glennow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis.  Eur Respir J. 1988;  1 351-355
    PubMedGoogle Scholar
  • 138 Hansen N CG, Skriver A, Brorsen-Ries L. et al . Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis.  Respir Med. 1994;  88 531-535
    CrossrefPubMedGoogle Scholar
  • 139 Pela R, Calcagni A M, Subiaco S. et al . N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD.  Respiration. 1999;  66 495-500
    CrossrefPubMedGoogle Scholar
  • 140 Grandjean E M, Berthet P, Ruffmann R. et al . Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A metaanalysis of published double blind, placebo-controlled clinical trials.  Clin Therapeutics. 2000;  22 209-221
    PubMedGoogle Scholar
  • 141 Stey C, Steuer J, Bachmann S. et al . The effect of oral N-acetylcysteine in chronic bronchitis - a quantitative systematic review.  Eur Respir J. 1999;  14 (Suppl. 30) 381S
    PubMedGoogle Scholar
  • 142 Poole P J, Black P N. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease.  BMJ. 2001;  322 1-6
    CrossrefPubMedGoogle Scholar
  • 143 Olivieri D, Zavattini G, Tomasini G. et al . Ambroxol for the prevention of chronic bronchitis exazerbations: long term multicenter trial.  Respiration. 1987;  51 (Suppl 1) 42-51
    PubMedGoogle Scholar
  • 144 Collet J P, Shapiro S, Ernst P. et al . Effect of an immunostimulating agent on acute exacerbations and hospitalizations in COPD patients.  Am J Respir Crit Care Med. 1997;  156 1719-1724
    PubMedGoogle Scholar
  • 145 Anthonisen N R. Editoral. OM-85BV for COPD.  Am J Respir Crit Care Med. 1997;  156 1713-1714
    PubMedGoogle Scholar
  • 146 Irwin R S, Boulet L P, Cloutier M M. et al . Managing cough as a defense mechanism and as a symptom: a consensus panel report of the American College of Chest Physicans.  Chest. 1998;  114 133S-181S
    PubMedGoogle Scholar
  • 147 Bardsley P A, Howard P, DeBacker W. et al . Two years treatment with almitrine bismesylate in patients with hypoxic chronic obstructive airways disease.  Eur Respir J. 1991;  4 308-310
    PubMedGoogle Scholar
  • 148 Watanabe S, Kanner R E, Cutillo A G. et al . Long-term effect of almitrine bismesylate in patients with hypoxemic chronic obstructive pulmonary disease.  Am J Respir Dis. 1989;  140 1269-1273
    PubMedGoogle Scholar
  • 149 Winkelmann B R, Kullmer T H, Kneissl D G. et al .Low-dose almitrine bismesylate in the treatment of hypoxemia due to chronic obstructive pulmonary disease. Chest 105: 1383-1391
    Google Scholar
  • 150 Eiser N, Denman W T, West C. et al . Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the “pink puffer” syndrome.  Eur Respir J. 1991;  4 926-931
    PubMedGoogle Scholar
  • 151 Young I H, Daviskas E, Keena V A. Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease.  Thorax. 1989;  44 387-390
    PubMedGoogle Scholar
  • 152 Rice K L, Kronenberg R S, Hedemark L L. et al . Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction.  Br J Dis Chest. 1987;  81 287-292
    CrossrefPubMedGoogle Scholar
  • 153 Woodcock A A, Gross E R, Gellert A A. et al . Effects of dihydrocodeine, alcohol and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases.  N Engl J Med. 1981;  305 1611-1616
    PubMedGoogle Scholar
  • 154 Poole P J, Veale A G, Black P N. The effect of sustained release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 1998;  157 1877-1880
    PubMedGoogle Scholar
  • 155 Schönhofer B, Suchi S, Haidl P. et al . Eine Epidemiologie zum Stellenwert von oral appliziertem Morphium als Therapieform des schwergradigen Lungenemphysems vom Pink-Puffer-Typ.  Med Klin. 2001;  96 325-330
    PubMedGoogle Scholar
  • 156 Alpha-1-Antitrypsin Deficiency Registry Group . Survival and FEV1 decline in individuals with severe deficiency of a1-antitrypsin.  Am J Respir Crit Care Med. 1998;  158 49-59
    PubMedGoogle Scholar
  • 157 Seersholm N, Kokjensen A. Clinical features and prognosis of life time non-smokers with severe α1-antitrypsin deficiency.  Thorax. 1998;  53 265-268
    CrossrefPubMedGoogle Scholar
  • 158 Wencker M, Banik N, Buhl R. Long-term treatment of α1-antitrypsin deficiency related pulmonary emphysema with human α1-antitrypsin.  Eur Respir J. 1998;  11 428-433
    CrossrefPubMedGoogle Scholar
  • 159 Incalci R A, Caradonna P, Ranieri P. et al . Correlates of osteoporosis in chronic obstructive pulmonary disease.  Respir Med. 2000;  94 1079-1084
    PubMedGoogle Scholar
  • 160 American College of Rheumatology ad hoc Committee on glucocorticoid-induced osteoporosis . Recommendations for the prevention and treatment of glucocortocoid-induced osteoporosis.  Arthritis Rheumatism. 2001;  44 1496-1503
    PubMedGoogle Scholar
  • 161 Engelken M PKJ, Schols A MWJ, Baker W C. et al . Nutritional depletion in relation to respiratory and peripheral muscle function in outpatients with COPD.  Eur Respir J. 1994;  7 1793-1797
    CrossrefPubMedGoogle Scholar
  • 162 Schols A MWJ, Soeters P B, Dingemans A MC. et al . Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation.  Am Rev Respir Dis. 1993;  147 1187-1196
    PubMedGoogle Scholar
  • 163 Wilson D O, Rogers R M, Wright E C. et al . Body weight in chronic obstructive pulmonary disease. The National Institutes of Health intermittend positive-pressure breathing trial.  Am Rev Respir Dis. 1989;  139 1435-1438
    PubMedGoogle Scholar
  • 164 Wouters E FM, Schols A MWJ. Nutritional depletion in COPD.  Eur Respir Rev. 1997;  7 60-65
    PubMedGoogle Scholar
  • 165 Fitting J W. Nutritional support in chronic obstructive lung disease.  Thorax. 1992;  47 141-143
    PubMedGoogle Scholar
  • 166 Hunter A BN, Carey M A, Lorch H W. The nutritional status of patients with chronic obstructive pulmonary disease.  Am Rev Respir Dis. 1985;  132 1347-1365
    PubMedGoogle Scholar
  • 167 Gray-Donald K, Gibbone L, Shapiro S H. et al . Nutritional status and mortality in chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 1996;  153 961-966
    PubMedGoogle Scholar
  • 168 Baarends E M, Schols A MWJ, Mostert R. et al . Peak exercise in relation to tissue depletion in patients with chronic obstructive pulmonary disease.  Eur Respir J. 1997;  10 2807-2813
    CrossrefPubMedGoogle Scholar
  • 169 Shoup R, Dalshy G, Warner G. et al . Body composition and health related quality of life in patients with chronic obstructive airways disease.  Eur Respir J. 1997;  10 1576-1580
    CrossrefPubMedGoogle Scholar
  • 170 Schols A MWJ, Slangen J, Volorris A. et al . Weigth loss is a reversible factor in the prognosis of COPD.  Am J Respir Crit Care Med. 1998;  157 1791-1797
    CrossrefPubMedGoogle Scholar
  • 171 Efthimiou J, Fleming J, Gomes C. et al . The effect of supplementary oral nutrition in poorly nourished patients with chronic obstructive pulmonary disease.  Am Rev Respir Dis. 1988;  137 1075-1082
    CrossrefPubMedGoogle Scholar
  • 172 Rogers R M, Donahue M, Constantino J. Physiologic effects of oral supplemental feeding in malnourished patients with chronic obstructive pulmonary disease patients. Am Rev Respir Dis 145: 1511-1597
    Google Scholar
  • 173 Whittaker J S, Buckley C F, Road J D. The effects of re-feeding on peripheral and respiratory muscle function in malnourished chronic obstructive pulmonary disease patients.  Am Rev Respir Dis. 1990;  142 283-288
    PubMedGoogle Scholar
  • 174 Ries A L, Kaplan R M, Limberg T M. et al . Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease.  Ann Intern Med. 1995;  122 823-832
    CrossrefPubMedGoogle Scholar
  • 175 Toshima M C, Kaplan R M, Ries A L. Experimental evaluation of rehabilitation in chronic obstructive pulmonary disease. Short term effects on exercise endurance and health status.  H Psychol. 1999;  9 237-252
    PubMedGoogle Scholar
  • 176 Gallefoss F, Bakke P S. How does patient education and self management among asthmatics and patients with chronic obstructive pulmonary disease affect medication?.  Am J Respir Crit Care Med. 1999;  160 2000-2005
    PubMedGoogle Scholar
  • 177 Lacasse Y, Guyatt G H, Goldstein R S. The components of a rehabilitation program. A systematic review.  Chest. 1997;  111 1077-1088
    PubMedGoogle Scholar
  • 178 Dhein Y, Birkenmaier A, Otte B. et al . Evaluation of a structured education programme (AFBE) for patients with mild to moderate COPD under outpatient conditions.  Am J Respir Crit Care Med. 2002;  165 A420
    PubMedGoogle Scholar
  • 179 Murray J F. The ketch-up bottle method.  N Engl J Med. 1979;  300 1155-1157
    PubMedGoogle Scholar
  • 180 Anthonisen P, Ries P, Sogaard-Andersen T. The value of lung physiotherapy in the treatment of acute exacerbations in chronic bronchitis.  Acta Med Scand. 1964;  145 715-719
    PubMedGoogle Scholar
  • 181 Graham W, Bradley G A. Efficacy of chest physiotherapy and intermittent positive-pressure breathing in the resolution of pneumonia.  N Eng J Med. 1978;  299 624-627
    PubMedGoogle Scholar
  • 182 King M, Philips D M, Gron D. et al . Enhanced tracheal mucus clearance with high frequency chest wall percussion.  Am Rev Respir Dis. 1983;  128 511-515
    PubMedGoogle Scholar
  • 183 Pryer J A. Physiotherapy for airway clearance in adults.  Eur Respir J. 1999;  14 1418-1424
    CrossrefPubMedGoogle Scholar
  • 184 Cegla U H, Petzow A. Physiotherapie mit dem VRP1 bei chronisch obstruktiven Atemwegserkrankungen - Ergebnisse einer multizentrischen Vergleichsstudie.  Pneumologie. 1993;  47 636-639
    PubMedGoogle Scholar
  • 185 App E M, Wunderlich M O, Lohse P. et al . Oszillierende Physiotherapie bei Bronchialerkrankungen - rheologischer und antientzündlicher Effekt.  Pneumologie. 1999;  53 1-12
    PubMedGoogle Scholar
  • 186 Cegla U H, Bautz M, Fröde G. et al . Physiotherapie bei Patienten mit COPD und tracheobronchialer Instabilität - Vergleich zweier oszillierender PEP-Systeme (RC-Cornet, VRP1-Destin).  Pneumologie. 1997;  51 129-136
    PubMedGoogle Scholar
  • 187 ACCP/AAC/VPR Pulmonary Rehabilitation Guidelines Panel . Pulmonary Rehabilitation.  Chest. 1997;  112 1363-1395
    PubMedGoogle Scholar
  • 188 American Thoracic Society . Pulmonary Rehabilitation.  Am J Respir Crit Care Med. 1999;  159 1666-1682
    PubMedGoogle Scholar
  • 189 Lacasse Y, Wong E, Guyatt G H. et al . Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease.  Lancet. 1996;  348 1115-1119
    CrossrefPubMedGoogle Scholar
  • 190 Hass A, Cardon H. Rehabilitation in chronic obstructive pulmonary disease: 5 year study of 252 patients.  Med Clin North Am. 1969;  53 593-606
    PubMedGoogle Scholar
  • 191 Sahn S A, Nett L M, Petty T L. Ten-year follow-up of a comprehensive rehabilitation programme for severe COPD.  Chest. 1980;  77 311-314
    PubMedGoogle Scholar
  • 192 Wedzicha J A, Bestall J C, Garrod R. et al . Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale.  Eur Respir J. 1998;  12 363-369
    CrossrefPubMedGoogle Scholar
  • 193 Young P, Dewse M, Fergusson W. et al . Respiratory rehabilitation in chronic obstructive pulmonary disease: predictors of non-adherence.  Eur Respir J. 1999;  13 867-872
    CrossrefPubMedGoogle Scholar
  • 194 Bergmann K, Fischer C J, Schmitz M. et al . Die stationäre Rehabilitation für Erwachsene. Zielsetzung - Diagnostik und therapeutische Standards - Forschungsbedarf.  Pneumologie. 1997;  51 523-532
    PubMedGoogle Scholar
  • 195 Szczepanski R, Taube K, Junggeburth J. et al . Ambulante wohnortnahe pneumologische Prävention und Rehabilitation bei obstruktiven Atemwegserkrankungen - Stand, Perspektive und Forschungsbedarf.  Pneumologie. 1998;  52 476-482
    PubMedGoogle Scholar
  • 196 Goldstein R S, Gort E H, Stubbing D. et al . Randomized controlled trial of respiratory rehabilitation.  Lancet. 1994;  344 1394-1397
    CrossrefPubMedGoogle Scholar
  • 197 Wijkstra P J, van Atena R, Kraan J. et al . Quality of life in patients with chronic obstructive pulmonary disease improve after rehabilitation at home.  Eur Respir J. 1994;  7 307-311
    PubMedGoogle Scholar
  • 198 McGavin C R, Gapta S P, Lloyd E L. et al . Physical rehabilitation for the chronic bronchitis. Results of a controlled trial of exercises in the home.  Thorax. 1977;  32 307-311
    PubMedGoogle Scholar
  • 199 Griffiths T L, Burr M L, Campbell I A. et al . Results at 1 year of out-patient multidisciplinary pulmonary rehabilitation.  Lancet. 2000;  355 362-368
    CrossrefPubMedGoogle Scholar
  • 200 Worth H, Meyer A, Folgering H. et al . Empfehlungen der Deutschen Atemwegsliga zum Sport und körperlichen Training bei Patienten mit obstruktiven Atemwegserkrankungen.  Pneumologie. 2000;  54 61-67
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 201 Bernhard S, Whittom F, Leblanc P. et al . Aerobic and strength training in patients with chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 1999;  159 896-901
    PubMedGoogle Scholar
  • 202 Belman M J, Botnick W C, Nathan S D. et al . Ventilatory load characteristics during ventilatory muscle training.  Am J Respir Crit Care Med. 1994;  149 925-929
    PubMedGoogle Scholar
  • 203 Foglio K, Bianchi L, Bruletti G. et al . Long-term effectiveness of pulmonary rehabilitation in patients with chronic airways obstruction.  Eur Respir J. 1999;  13 125-132
    CrossrefPubMedGoogle Scholar
  • 204 Young P, Dewse M, Ferguson W. et al . Improvements in outcomes for chronic obstructive pulmonary disease (COPD) attributable to a hospital-based respiratory rehabilitation programme.  Aus NZ J Med. 1999;  29 59-65
    PubMedGoogle Scholar
  • 205 Carter R, Blevins W, Stocks J. et al . Cost and quality issues related to the management of COPD.  Sem Resp Med. 1999;  20 199-212
    PubMedGoogle Scholar
  • 206 Magnussen H, Goeckenjan G, Köhler D. et al . Leitlinien zur Sauerstoff-Langzeit-Therapie.  Pneumologie. 2001;  55 454-464
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 207 Report of the Medical Research Council Working Party . Long-term domiciliary oxygen in chronic cor pulmonale complicating chronic bronchitis and emphysema.  Lancet. 1981;  1 681-685
    PubMedGoogle Scholar
  • 208 Nocturnal oxygen therapy trial group . Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease.  Ann Intern Med. 1980;  93 191-198
    PubMedGoogle Scholar
  • 209 Weitzenblum E, Sautegeau A, Ehrhart M. et al . Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease.  Am Rev Respir Dis. 1985;  131 493-498
    PubMedGoogle Scholar
  • 210 Leach R M, Davidson A C, Chinn S. et al . Portable liquid oxygen and exercise ability in severe respiratory disability.  Thorax. 1992;  47 78-789
    PubMedGoogle Scholar
  • 211 Tarpy S P, Celli B R. Long-term oxygen therapy.  N Engl J Med. 1995;  333 710-714
    CrossrefPubMedGoogle Scholar
  • 212 Pelletier Fleury N, Laone J L, Fleury B. et al . The cost of treating COPD patients with long-term oxygen therapy in a French population.  Chest. 1996;  110 411-416
    CrossrefPubMedGoogle Scholar
  • 213 Heaney L G, McAllister D, MacMahon J. Cost minimisation analysis of provision of oxygen at home: are the drug tariff guidelines cost effective?.  BMJ. 1999;  319 19-23
    PubMedGoogle Scholar
  • 214 Donahoe M, Rogers R M. Nutritional assessment and support in chronic pulmonary disease.  Clin Chest Med. 1990;  11 487-504
    PubMedGoogle Scholar
  • 215 Köhler D, Criée C-P, Raschke F. Leitlinien zur häuslichen Sauerstoff- und Heimbeatmungstherapie.  Pneumologie. 1996;  50 927-931
    PubMedGoogle Scholar
  • 216 Simmonds A K, Elliot M W. Outcome of domiciliary nasal intermittent positive pressure ventilation in restrictive and obstructive disorders.  Thorax. 1995;  50 604-609
    CrossrefPubMedGoogle Scholar
  • 217 Meecham Jones D J, Paul E A, Jones P W. et al . Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD.  Am J Respir Crit Care Med. 1995;  152 538-544
    CrossrefPubMedGoogle Scholar
  • 218 Consensus Conference . Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation. A consensus conference report.  Chest. 1999;  116 521-534
    CrossrefPubMedGoogle Scholar
  • 219 Mehran R J, Deslauriers J. Indications for surgery and patient work-up for bullectomie.  Chest Surg Clin N Am. 1995;  5 717-734
    PubMedGoogle Scholar
  • 220 Hughes J A, Hutchison D M, MacArthur D CS. et al . Long-term changes in lung function after surgical treatment of bullos emphysema in smokers and exsmokers.  Thorax. 1986;  39 140
    PubMedGoogle Scholar
  • 221 Brantigan O C, Kress M B, Müller E A. A surgical approach to pulmonary emphysema.  Dis Chest. 1961;  39 485-501
    PubMedGoogle Scholar
  • 222 Cooper J D, Trulock E P, Triantafillou A N. et al . Bilateral pneumonectomy (volume reduction) for chronic obstructive pulmonary disease.  J Thorac Cardiovasc Surg. 1995;  109 106-119
    PubMedGoogle Scholar
  • 223 Geddes D, Davies M, Koyama H. et al . Effect of lung volume reduction surgery in patients with severe emphysema.  N Engl J Med. 2000;  343 239-245
    CrossrefPubMedGoogle Scholar
  • 224 Benditt J O, Albert R K. Surgical options for patients with advanced emphysema.  Clin Chest Med. 1997;  18 577-593
    CrossrefPubMedGoogle Scholar
  • 225 A National Emphysema Treatment Trial Research Group . Patients at high risk of death after lung-volume-reduction surgery.  N Engl J Med. 2001;  345 1075-1083
    CrossrefPubMedGoogle Scholar
  • 226 Cassina P C, Teschler H, Konietzko N. et al . Two-year results after lung volume reduction surgery in alpha-1-antitrypsin deficiency versus smoker's emphysema.  Eur Respir J. 1998;  12 1028-1032
    CrossrefPubMedGoogle Scholar
  • 227 Thurnheer R, Engel H, Weder W. et al . Role of lung perfusion scintigraphy in relation to chest computed tomography and pulmonary function in the evaluation of candidates for lung volume reduction surgery.  Am J Respir Crit Care Med. 1999;  159 301-310
    CrossrefPubMedGoogle Scholar
  • 228 Brenner M, McKenna R JJ, Gelb A F. et al . Rate of FEV1 change following lung volume reduction surgery.  Chest. 1998;  113 652-659
    PubMedGoogle Scholar
  • 229 McKenna R J, Brenner M, Fischel R J. et al . Should lung volume reduction for emphysema be unilateral or bilateral?.  J Thorac Cardivasc Surg. 1996;  112 1331-1339
    CrossrefPubMedGoogle Scholar
  • 230 Sciurba F C. Early and long-term functional outcomes following lung volume reduction surgery.  Clin Chest Med. 1997;  18 259-276
    CrossrefPubMedGoogle Scholar
  • 231 Stamatis G, Teschler H, Fechner S. et al . Bilaterale Lungenvolumenreduktion bei Patienten mit schwerem Lungenemphysem.  Pneumologie. 1996;  50 448-452
    PubMedGoogle Scholar
  • 232 Wisser W, Deviatko E, Simon N. et al . Lung transplantation following lung volume reduction surgery.  J Heart Lung Transplant. 2000;  19 480-487
    PubMedGoogle Scholar
  • 233 Theodore J, Lewiston N. Lung transplantation comes of age.  N Engl J Med. 1990;  322 772-774
    PubMedGoogle Scholar
  • 234 Trulock E P. Lung transplantation.  Am J Respir Crit Care Med. 1997;  155 789-818
    CrossrefPubMedGoogle Scholar
  • 235 Division of transplantation Bo .1995 Annual report of the US scientific registry for transplant recipients and the organ procurement and transplantation network. Transplant data: 1988 - 1994. Health Resources and Services Administration. US Department of Health and Human services 1995
    Google Scholar
  • 236 Hosenpud J D, Novick R J, Bennett L E. et al . The registry of the international society for heart and lung transplantation: twelfth official report.  J Heart Lung Transplant. 1996;  15 655-674
    PubMedGoogle Scholar
  • 237 Hosenpud J D, Bennett L E, Keck B M. et al . Effects of diagnosis on survival benefit of lung transplantation for end-stage lung disease.  Lancet. 1998;  3 24-27
    PubMedGoogle Scholar
  • 238 Niedermeier J, Bewig B, Bickhardt T. et al . Lungen- und Herz- und Lungentransplantation. Leitlinien zur Indikationsstellung und Präoperativen Diagnostik.  Pneumologie. 2001;  55 396-400
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 239 Trulok E P. Lung transplantation for COPD.  Chest. 1998;  113 269-276
    PubMedGoogle Scholar
  • 240 Ramsey S D, Patrick D L, Albert R K. et al . The cost-effectiveness of lung transplantation: a pilot study.  Chest. 1995;  108 1594-1601
    CrossrefPubMedGoogle Scholar
  • 241 Molken M P, van Doorslaer E K, Rutten F F. Economic appraisal of asthma and COPD care: a literature review 1980 - 1991.  Soc Sci Med. 1992;  35 161-175
    CrossrefPubMedGoogle Scholar
  • 242 Kroshus T J, Bolmann III R M, Kshettry V R. Unilateral volume reduction after single-lung transplantation for emphysema.  Ann Thorac Surg. 1996;  62 363-368
    CrossrefPubMedGoogle Scholar
  • 243 Anderson M B, Kriett J M, Kapelanski D P. et al . Volume reduction surgery in the native lung after single lung transplantation for emphysema.  J Heart Lung Transplant. 1997;  16 752-757
    PubMedGoogle Scholar
  • 244 Anthonisen N R, Manfreda J, Warren C P. et al . Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.  Ann Intern Med. 1987;  106 196-204
    CrossrefPubMedGoogle Scholar
  • 245 Regueiro C R, Hamel M B, Davis R B. et al . A comparison of generalist and pulmonologist care for patients hospitalized with severe chronic obstructive pulmonary disease: resource intensity, hospital costs and survival.  Am J Med. 1998;  105 366-372
    CrossrefPubMedGoogle Scholar
  • 246 Gibson P G, Wlodarczyk J H, Wilson A J. et al . Severe exacerbations of chronic obstructive airways disease: health resource use in general practice and hospital.  J Qual Clin Pract. 1998;  18 125-133
    PubMedGoogle Scholar
  • 247 Mushlin A I, Black E A, Connolly C A. et al . The necessary length of hospital stay for chronic pulmonary disease.  JAMA. 1991;  266 80-83
    CrossrefPubMedGoogle Scholar
  • 248 Connors A F, Dawson N V, Thomas C. et al . Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators.  Am J Respir Crit Care Med. 1996;  154 959-967
    CrossrefPubMedGoogle Scholar
  • 249 Kong G K, Belman M J, Weingarten S. Reducing length of stay for patients hospitalized with exacerbation of COPD by using a practice guideline.  Chest. 1997;  111 89-94
    PubMedGoogle Scholar
  • 250 Fuso L, Incalzi R A, Pistelli R. et al . Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease.  Am J Med. 1995;  98 272-277
    CrossrefPubMedGoogle Scholar
  • 251 Seneff M G, Wagner D P, Wagner R P. et al . Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease.  JAMA. 1995;  274 1852-1857
    CrossrefPubMedGoogle Scholar
  • 252 MacFarlane J T, Colville A, Macfarlane R M. et al . Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community.  Lancet. 1993;  341 511-514
    CrossrefPubMedGoogle Scholar
  • 253 Stockley R A, O'Brien C, Pye A. et al . Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD.  Chest. 2000;  117 1638-1645
    CrossrefPubMedGoogle Scholar
  • 254 Seemungal T R, Harpen-Owen R, Bhownik A. et al . Respiratory viruses, symptoms and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2001;  164 1618-1623
    CrossrefPubMedGoogle Scholar
  • 255 Anderson H R, Spix C, Medina S. et al . Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project.  Eur Respir J. 1997;  10 1064-1071
    CrossrefPubMedGoogle Scholar
  • 256 Emerman C L, Connors A F, Lukens T W. et al . Relationship between arterial blood gases and spirometry in acute exacerbations of chronic obstructive pulmonary disease.  Ann Emerg Med. 1989;  18 523-527
    PubMedGoogle Scholar
  • 257 Emerman C L, Effron D, Lukens T W. Spirometric criteria for hospital admission of patients with acute exacerbation of COPD.  Chest. 1991;  99 595-599
    PubMedGoogle Scholar
  • 258 Emerman C L, Lukes T W, Effron D. Physician estimation of FEV1 in acute exacerbation of COPD.  Chest. 1994;  105 1709-1712
    PubMedGoogle Scholar
  • 259 Emerman C L, Cydulka R K. Use of peak expiratory flow rate in emergency department evaluation of acute exacerbation of chronic obstructive pulmonary disease [see comments].  Ann Emerg Med. 1996;  27 159-163
    PubMedGoogle Scholar
  • 260 Rice K L, Leatherman J W, Duane P G. et al . Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. A controlled trial.  Ann Intern Med. 1987;  107 305-309
    PubMedGoogle Scholar
  • 261 Barbera J A, Reyes A, Roca J. et al . Effect of intravenously administered aminophylline on ventilation/perfusion inequality during recovery from exacerbations of chronic obstructive pulmonary disease.  Am Rev Respir Dis. 1992;  145 1328-1333
    PubMedGoogle Scholar
  • 262 Mahon J L, Laupacis A, Hodder R V. et al . Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice.  Chest. 1999;  115 38-48
    CrossrefPubMedGoogle Scholar
  • 263 Loberes P, Ramis L, Montserrat J M. et al . Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease.  Eur Respir J. 1988;  1 536-539
    PubMedGoogle Scholar
  • 264 Emerman C L, Connors A F, Lukens T W. et al . Theophylline concentrations in patients with acute exacerbation of COPD [see comments].  Am J Emerg Med. 1990;  8 289-292
    CrossrefPubMedGoogle Scholar
  • 265 Eller J, Ede A, Schaberg T. et al . Infective exacerbations of chronic bronchitis.  Chest. 1998;  113 1542-1548
    CrossrefPubMedGoogle Scholar
  • 266 Vogel F, Worth H, Adam D. et al . Rationale Therapie bakterieller Atemwegsinfektionen. Empfehlungen einer Expertengruppe der Paul-Ehrlich-Gesellschaft für Chemotherapie und der Deutschen Atemwegsliga.  Chemother J. 2000;  9 3-23
    PubMedGoogle Scholar
  • 267 Thompson W H, Nielson C P, Carvalho P. et al . Controlled trial of oral prednisolone in outpatients with acute COPD exacerbation.  Am J Respir Crit Care Med. 1996;  154 407-412
    PubMedGoogle Scholar
  • 268 Davies L, Angus R M, Calverley P M. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial.  Lancet. 1999;  354 456-460
    CrossrefPubMedGoogle Scholar
  • 269 Niewoehner D E, Erbland M L, Deupree R H. et al . Effect of systemic glucocorticoids on exacxerbations of chronic obstructive pulmonary disease.  N Engl J Med. 1999;  340 1941-1947
    CrossrefPubMedGoogle Scholar
  • 270 Bach P B, Brown C, Gelfand S E. et al . Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence.  Ann Intern Med. 2001;  134 600-620
    PubMedGoogle Scholar
  • 271 Rossi A, Gottfried S B, Zocci L. et al . Respiratory mechanics in mechanically ventilated patients with respiratory failure.  J Appl Physiol. 1985;  58 1849-1858
    PubMedGoogle Scholar
  • 272 Georgopoulos D, Rossi A, Moxham J. Ventilatory support in chronic obstructive pulmonary disease.  Eur Respir Mon. 1998;  7 189-208
    PubMedGoogle Scholar
  • 273 Bott J, Carroll M P, Conway J H. et al . Randomized controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease.  Lancet. 1993;  341 1555-1557
    CrossrefPubMedGoogle Scholar
  • 274 Brochard L, Mancebo J, Wysocki M. et al . Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease.  N Engl J Med. 1995;  33 817-822
    PubMedGoogle Scholar
  • 275 Kramer N, Meyer T J, Meharg J. et al . Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure.  Am J Respir Crit Care Med. 1995;  151 1799-1806
    CrossrefPubMedGoogle Scholar
  • 276 Barbé F, Togores B, Rubi M. et al . Noninvasive ventilatory support does not facilitate recovery from acute respiratory failure in chronic obstructive pulmonary disease.  Eur Respir J. 1996;  9 1240-1245
    CrossrefPubMedGoogle Scholar
  • 277 Plant P K, Owen J L, Elliott M W. Early use of non-invasive ventilation (NIV) for acute exacerbations of COPD on general respiratory wards: a multicenter randomized controlled trial.  Lancet. 2000;  355 1931-1935
    CrossrefPubMedGoogle Scholar
  • 278 Nava S, Ambrosino N, Clini E. et al . Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease. A randomized, controlled trial.  Ann Intern Med. 1998;  128 721-728
    CrossrefPubMedGoogle Scholar
  • 279 Stoller J K, Lange P A. Inpatient management of chronic obstructive pulmonary disease.  Respir Care Clin N Am. 1998;  4 425-438
    PubMedGoogle Scholar
  • 280 Peach H, Pathy M S. Follow-up study of disability among elderly patients discharged from hospital with exacerbations of chronic bronchitis.  Thorax. 1981;  36 585-589
    PubMedGoogle Scholar
  • 281 Friedman M, Serby C W, Menjoge S S. et al . Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD.  Chest. 1999;  115 635-641
    CrossrefPubMedGoogle Scholar
  • 282 Mahler D A, Donohue J F, Barbee R A. et al . Efficacy of salmeterol xinafoate in the treatment of COPD.  Chest. 1999;  115 957-965
    CrossrefPubMedGoogle Scholar
  • 283 Morgan W KG, Reger R B. Chronic airflow limitation and occupation. In: Cherniack NS (Hrsg.): Chronic obstructive pulmonary disease Philadelphia: Saunders 1991
    Google Scholar
  • 284 Nowak D. Berufsbedingte obstruktive Atemwegserkrankung (BK4301 und 4302) gutachterliche Anmerkungen zum Krankheitsbegriff und zur MdE.  Arbeitsmed Sozialmed Umweltmed. 2000;  35 164-167
    PubMedGoogle Scholar
  • 285 Morfeld P, Piekarski C. Chronische Bronchitis und Emphysem als Berufskrankheit der Steinkohlenbergleute. Schriftenreihe Zentralblatt für Arbeitsmedizin, Haefer 1998
    Google Scholar
  • 286 Nowak D. Informationen zur neuen Berufskrankheit 4111: „Chronische obstruktive Bronchitis oder Emphysem von Bergleuten unter Tage im Steinkohlenbergbau bei Nachweis der Einwirkung einer kumulativen Feinstaubdosis von in der Regel 100 [(mg/m3) × Jahre]”. Pneumologie 1996: 652-654
    Google Scholar
  • 287 Kroidl R F, Nowak D, Seysen U. Bewertung und Begutachtung in der Pneumologie. Thieme 1999
    Google Scholar
  • 288 Bundesministerium für Arbeit und Sozialordnung .Anhaltspunkte für die ärztliche Gutachtertätigkeit im sozialen Entschädigungsrecht und nach dem Schwerbehindertengesetz. Köllen,. 1996
    Google Scholar

Prof. Dr. med. H. Worth

Medizinische Klinik I · Klinikum Fürth

Jakob-Henle-Str. 1

90766 Fürth

eMail: med1@klinikum-fuerth.de